http://www.businesswire.com/news/home/20160411005076/en/Merz-Neurosciences-Announces-Survey-Findings-Showcase-Lack
Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced findings from a new survey of more than 1,000 US adults, revealing that overall awareness of the signs and symptoms of adult Upper Limb Spasticity (ULS) is low among Americans. The survey was conducted by Harris Poll and commissioned by Merz Neurosciences. In adults with upper limb spasticity, there is an imbalance of signals from the brain to the muscles, which causes stiffness and spasms. This can lead to abnormal arm or hand positions, uncomfortable movement, and pain1.
“Adult ULS is a serious condition that impacts many Americans after stroke, injury, and other neurological disorders, preventing them from being able to do simple, day-to-day activities, like getting dressed or putting on deodorant,” said Robyn Moore, CEO of the National Stroke Association. “Since ULS can happen months after the initial stroke or injury, it’s critical that family members and caregivers be able to recognize the symptoms.”“Adult ULS is a serious condition that impacts many Americans after stroke, injury, and other neurological disorders, preventing them from being able to do simple, day-to-day activities, like getting dressed or putting on deodorant”Tweet this
The national survey was conducted online among 1,043 U.S. adults from November 9-20, 2015 and asked adults about their familiarity with ULS. The survey found:
- More than 8 in 10 Americans (83%) say they have never heard of ULS.
- More than 2 in 3 Americans (67%) admit not being sure of the early signs and symptoms of ULS.
- About 1 in 3 (32%) identified at least one condition that could lead to ULS; still, the majority (59%) report being unclear on the causes of ULS.
- About 1 in 4 believe that upper limb spasticity is extremely rare in people who have had a stroke.
- Further, about 1 in 4 (24% of Americans and 28% of the undiagnosed who are aware of ULS) believe adults who have suffered from a stroke should not be concerned about upper limb spasticity.
Merz Neurosciences recently announced FDA approval of Xeomin® (incobotulinumtoxinA) for the treatment of upper limb spasticity in adults. In clinical studies, treatment with Xeomin for adult ULS resulted in statistically significant improvements in muscle tone, with a safety profile similar to that observed for other Xeomin indications.
For more information, please see XEOMIN full Prescribing Information and Medication Guide.
Survey Methodology
This survey was conducted online within the United States by Harris Poll on behalf of Merz Neurosciences between November 9-20, 2015 among 1,043 U.S. adults 18+. Figures for age, sex, race/ethnicity, education, region and household income were weighted, where necessary, to bring them into line with their actual proportions in the population. Propensity score weighting was used to adjust for respondents’ propensity to be online.
All sample surveys and polls, whether or not they use probability (random) sampling, are subject to multiple sources of error which are most often not possible to quantify or estimate, including sampling error, coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Therefore, the words “margin of error” are avoided as they are misleading. All that can be calculated are different possible sampling errors with different probabilities for pure, unweighted, random samples with 100% response rates. These are only theoretical because no published polls come close to this ideal.
Respondents for this survey were selected from among those who have agreed to participate in Harris Poll surveys. Because the sample is based on those who agreed to participate in the panel, no estimates of theoretical sampling error can be calculated.
No comments:
Post a Comment